Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AVANAL07163
Previous Study | Return to List | Next Study

Efficacy and Tolerability Study of Avanafil in Russia (CEDAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02503306
Recruitment Status : Completed
First Posted : July 20, 2015
Last Update Posted : March 17, 2016
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objective:

o To assess the change in percent of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse between the run-in period and treatment period:

  • The change in percent of sexual attempts in which subjects are able to insert the penis into the partner's vagina.
  • The change in score on the erectile function (EF) domain of the International Index of Erectile Function (IIEF) questionnaire.

Secondary Objective:

o To evaluate the safety and tolerability of avanafil in patients with erectile dysfunction (ED).


Condition or disease Intervention/treatment Phase
Sexual Function and Fertility Disorders NEC-Erectile Dysfunction Drug: AVANAFIL Drug: placebo Phase 3

Detailed Description:
The total study duration per patient will be up to 12 weeks, consisting of an 8-week treatment period and a 4-week run-in period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 189 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Trial on Efficacy and Tolerability of Two Different Single Doses of Avanafil in Russia
Study Start Date : July 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : March 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Avanafil

Arm Intervention/treatment
Experimental: Avanafil dose 1
Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Drug: AVANAFIL
Pharmaceutical form:tablets Route of administration: oral

Experimental: Avanafil dose 2
Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Drug: AVANAFIL
Pharmaceutical form:tablets Route of administration: oral

Placebo Comparator: Placebo
Administered 30 minutes prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Drug: placebo
Pharmaceutical form:tablets Route of administration: oral




Primary Outcome Measures :
  1. Change in the percentage of sexual attempts in which subjects are able to maintain an erection of sufficient duration to have successful intercourse [ Time Frame: 12 weeks ]
  2. Change in the percentage of sexual attempts in which subjects are able to insert the penis into the partner's vagina [ Time Frame: 8 weeks ]
  3. Change from baseline in EF score [ Time Frame: baseline and 8 weeks ]

Secondary Outcome Measures :
  1. Change from baseline in IIEF-EF risk scores [ Time Frame: baseline and 8 weeks ]
  2. Proportion of patients with adverse events [ Time Frame: 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male subjects, age ≥18 years.
  • Minimum 6-month history of mild to severe erectile dysfunction prior to the enrollment into the study.
  • Subject is in a monogamous, heterosexual relationship for at least 3 months prior to the enrollment into the study.
  • Subject agrees to make at least 4 sexual intercourse attempts per month.
  • Subject is willing and able to provide informed consent.

Exclusion criteria:

  • Allergy or hypersensitivity to avanafil, sildenafil, vardenafil, tadalafil, or any of the components of these drug products.
  • History of dose-limiting adverse effects during therapy with a phosphodiesterase-5 (PDE5) inhibitor or history of consistent treatment failure with other PDE5 inhibitors for therapy of ED.
  • Current or expected use of organic nitrates at any time during the study.
  • Previous or current (including while on treatment) antiandrogen therapy.
  • Use of ketoconazole, erythromycin, cimetidine, or any other prescription or over-the-counter drugs known to inhibit the activity of cytochrome P450 (CYP) 3A4 within 28 days prior to randomization or at any time during this study.
  • Androgen replacement therapy that has not been stable for at least 3 months.
  • Erectile dysfunction as a result of spinal cord injury or radical prostatectomy.
  • Untreated hypogonadism or serum total testosterone <325 ng/dL (early morning collection).
  • History of or predisposition to priapism (such as sickle cell disease, blood dyscrasias, or multiple myeloma).
  • Uncontrolled hypertension as evidenced by systolic blood pressure >170 mmHg or diastolic blood pressure >100 mmHg at screening.
  • Hypotension as evidenced by systolic blood pressure <90 mmHg or diastolic blood pressure <50 mmHg at screening.
  • Orthostatic hypotension as evidenced by reduction of 20 mmHg or more in systolic blood pressure, reduction of 10 mmHg or more in diastolic blood pressure, or evidence of cerebral hypoperfusion upon standing from a seated position.
  • Clinically evident penile lesions, abrasions, anatomical deformities such as penile fibrosis, Peyronie's disease, urinary tract or bladder infection, or sexually transmissible disease that the Investigator deems to be clinically significant.
  • History of drug, alcohol, or substance abuse within 12 months of entry.
  • Partners who are <18 years of age, who are nursing, who are known to be pregnant at screening, who wish to become pregnant during the study period, who have dyspareunia, and/or any other gynecologic problems or major medical conditions that would limit participation in sexual intercourse.
  • Evidence of any clinically significant medical, psychiatric, social, or other condition by history, physical examination, or laboratory studies that, in the opinion of the Investigator, would contraindicate the administration of study medication, affect compliance, interfere with study evaluations, limit study participation, contraindicate sexual activity, or confound the interpretation of study results.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02503306


Locations
Layout table for location information
Russian Federation
Moscow, Russian Federation
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT02503306     History of Changes
Other Study ID Numbers: AVANAL07163
U1111-1167-6889 ( Other Identifier: UTN )
First Posted: July 20, 2015    Key Record Dates
Last Update Posted: March 17, 2016
Last Verified: March 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders